Onychomycosis
Drug research and approvals for onychomycosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 6 studies of onychomycosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 3 drug trials for it since 2013.
- Recruiting worldwide: 6
- Trials authorized in Canada: 3
- FDA orphan approvals: 0
- EU medicines: 0
- In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates…NCT07898475 · Not reported · Dr. Amara Safdar · starts Oct 2, 2026
- URGO MICKAEL Filmogel, Topical Treatment of OnychomycosisNCT07828184 · Not applicable · CEN Biotech · starts Jan 28, 2026
- CLINICAL INVESTIGATION FOR THE EVALUATION OF EFFICACY AND SAFETY OF TWO PRODUCTS FOR THE TREATMENT OF ONYCHOMYCOSISNCT06689852 · Not applicable · Oystershell NV · starts Oct 30, 2024
- Isotretinoin Versus Excimer Light an Adjuvant in Treating OnychomycosisNCT06485505 · Phase 1 · Zagazig University · starts Jul 12, 2024
- A Study of ATB1651 in Adults With Mild to Moderate OnchomycosisNCT06327295 · Phase 2 · AmtixBio Co., Ltd. · starts Jul 1, 2024
- Safety and Efficacy of Next Science Gel on Toenail FungusNCT04042857 · Not applicable · Next Science TM · starts Jul 26, 2019
Approved 5
- TavaboroleLeucine-tRNA ligase inhibitor
- TerbinafineSqualene monooxygenase inhibitor
- ItraconazoleCytochrome P450 51 inhibitor
- EfinaconazoleLanosterol 14-alpha demethylase inhibitor
- CiclopiroxIron chelating agent
Phase 3 2
- Amorolfine
- BifonazoleLanosterol 14-alpha demethylase inhibitor
Phase 2 6
- LuliconazoleCytochrome P450 51 inhibitor
- AlbaconazoleLanosterol 14-alpha demethylase inhibitor
- NaftifineSqualene monooxygenase inhibitor
- PosaconazoleCytochrome P450 51 inhibitor
- Cetylpyridinium
- OteseconazoleLanosterol 14-alpha demethylase inhibitor
Phase 1 or earlier 2
- KetoconazoleCytochrome P450 51 inhibitor
- Levomenol
How its trials ended
148 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 62% met their primary endpoint, 0% missed it and 38% stopped early.
- Completed, result not reported8859%
- Status unknown2215%
- Ongoing1711%
- Met its primary endpoint139%
- Stopped: other or unclear64%
- Stopped: sponsor or business decision21%
| Jun 17, 2022 | A multi-center, double-blind, randomized, vehicle-controlled study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal…Terbinafine (MOB015B) | Moberg Pharma AB | Closed |
| Jul 22, 2019 | Long-term therapy/ extended prophylaxis with efinaconazole 10% nail solution for mild to moderate toenail onychomycosis caused by dermatophytes…Efinaconazole | Mediprobe Research Inc | Closed |
| Jul 27, 2016 | A multi-centre, double-blind, randomized, vehicle-controlled study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal…Terbinafine | Moberg Pharma AB | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA